JP Morgan Chase’s Kiniksa Pharmaceuticals KNSA Stock Holding History

JP Morgan Chase’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,000	Closed	-$581K	–	7590
2025 Q2	$581K	Hold	21,000	–	–	﹤0.01%	4695
2025 Q1	$466K	Buy	+21,000	New	+$432K	﹤0.01%	4824
2023 Q4	–	Sell	-30,000	Closed	-$521K	–	7705
2023 Q3	$521K	Hold	30,000	–	–	﹤0.01%	4450
2023 Q2	$422K	Buy	+30,000	New	+$402K	﹤0.01%	4591
2021 Q4	–	Sell	-30,000	Closed	-$342K	–	6811
2021 Q3	$342K	Buy	+30,000	New	+$391K	﹤0.01%	4936

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

JP Morgan Chase's KNSA Position: Q1 2026 in Review

JP Morgan Chase increased its Kiniksa Pharmaceuticals (KNSA) stake by 121% in Q1 2026, buying an estimated $2.6M and bringing the position to 107,017 shares worth $4.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3323.

JP Morgan Chase first reported a position in KNSA in Q3 2018 and has held it in 30 quarters since. The position peaked at $9.45M in Q4 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

JP Morgan Chase held 107,017 shares of Kiniksa Pharmaceuticals worth $4.89M as of Q1 2026.
JP Morgan Chase bought 58,620 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $2.6M.
Kiniksa Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3323 holding.
JP Morgan Chase first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
JP Morgan Chase's Kiniksa Pharmaceuticals position peaked at $9.45M in Q4 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.